OMT is currently defined as combination of high dose betablocker and high dose angiotensin converting-enzyme inhibitor, with the addition of a mineralocorticoid receptor antagonist in patients with persistent symptoms of heart failure [4]. The gene discussed is ACE; the disease is heart failure.